|
See related Aranesp inj information |
|
|
|
Manufacturer |
Amgen |
|
Distributor |
Hong Kong: LF Asia/Macau: Four Star |
|
Contents |
Darbepoetin α |
|
Indications |
Anaemia associated w/ chronic renal failure. Anaemia w/ nonmyeloid malignancies due to concomitant chemotherapy. |
|
Dosage |
Correction of anaemia 0.45 mcg/kg body wt as a single IV or SC dose once wkly. Cancer patients receiving chemotherapy 2.25 mcg/kg as a wkly SC dose. |
|
Contraindications |
Uncontrolled HTN. |
|
Special Precautions |
Monitor BP & Hb, presence of premonitory neurologic symptoms. Exclude folic acid or vit B12 deficiency. Severe rash, urticaria, pure red cell aplasia (discontinue). |
|
Adverse Drug Reactions |
HTN, hypotension, fever, chest pain, headache, myalgia, infection, diarrhea.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
B03XA02 - darbepoetin alfa ; Belongs to the class of other antianemic preparations. |
